Wednesday, March 30, 2011

Heart is First on LifeCradle Priority List

Heart is First on LifeCradle Priority ListOxford, MS 3/30/2011 (Penny PayDay) -- Allezoe Medical Holdings (OTC:ALZM) recently announced, in a press release, the additional members of its wholly-owned subsidiary Organ Transport Systems' Medical Advisory Board. As I write, shares of Allezoe Medical were up slightly at $2.46 per share on heavy volume of more than 7.8 million shares. The company has a market cap of $128 million and a 52-week range between $1.28 and $2.60 per share.

Also, recently, in a press release, Organ Transport Systems revealed that it is in preparations for clinical trials of its LifeCradle, beginning with applications of its technology to donor heart preservation. OTS has selected the heart as the first focus of its clinical trials due to the pressing need for heart sharing in light of the prevalence of heart disease and personal experiences of the Founder.

Organ Transport System's Executive Vice President Dr. Tom Franklin says, "OTS is very fortunate to have access to the experiences and wisdom of internationally renowned, seasoned professionals from the real world of organ transplantation to guide our product development and insertion of the LifeCradle into the organ procurement and preservation process."

Allezoe Medical Holdings is the holding company for Organ Transport Systems, Inc. Organ Transport Systems, Inc. (OTS), headquartered in Frisco, Texas, is a biomedical company engaged in developing, patenting, and commercializing portable hypothermic, oxygenated preservation and transport technology for human organs. OTS plans to redefine human organ transplantation through better preservation with its LifeCradle product line.

For more information, please visit: www.allezoe.com.

Distributed by IntelBuilder Social Media Platform

No comments:

Post a Comment